Scientific Advisory Board

Peter B. Dervan, Ph.D.

Dr. Dervan is the Bren Professor of Chemistry at the California Institute of Technology, where he served as the chair of the division of chemistry and chemical engineering from 1994 to 1999. He is recognized for creating a new field of bioorganic chemistry directed towards understanding the chemical principles for the sequence specific recognition of DNA.

Dr. Dervan is a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts & Sciences, the American Philosophical Society, and a Foreign Member of both the French and German Academies of Science. Among his countless awards and distinctions is the National Medal of Science, which he was awarded in 2006. He has served on numerous Scientific Advisory Boards, including that of Gilead Sciences, Inc.

Dr. Dervan earned his B.S. in chemistry from Boston College, his Ph.D. in physical organic chemistry from Yale University and spent a year at Stanford University as a National Institutes of Health Postdoctoral Fellow.

David Horne, Ph.D.
Co-founder, Meditope Biosciences

Dr. Horne is recognized for his scientific and research expertise, currently serving as vice provost and associate director of Beckman Research Institute of the City of Hope. He is internationally recognized for his work in natural products synthesis and medicinal chemistry. Since joining the Beckman Research Institute in 2006, Dr. Horne has held numerous leadership positions including interim director of the Beckman Research Institute and co-leader of the Developmental Cancer Therapeutics program at City of Hope's NCI-designated Comprehensive Cancer Center.

Dr. Horne's professional experience is complemented by his impressive academic achievements. He received his B.S. in chemistry from the University of California at Los Angeles, his Ph.D. in chemistry from the Massachusetts Institute of Technology and was a National Institutes of Health Postdoctoral Fellow at the California Institute of Technology. Prior to joining City of Hope, Dr. Horne was a faculty member in the department of chemistry at both Columbia University and Oregon State University.

Arthur D. Riggs, Ph.D.

Dr. Riggs is the Director Emeritus of the Beckman Research Institute at City of Hope (COH) and current Director of the Diabetes and Metabolism Research Institute at COH. He was the founding dean of the City of Hope's graduate school. He is also a member of the National Academy of Sciences.

Dr. Riggs worked with Genentech to express the first artificial genes, for somatostatin and insulin, in bacteria. His work helped form the bedrock of the modern biotechnology industry, enabling the large-scale manufacturing of protein drugs, like synthetic human insulin, and developing recombinant DNA techniques that are the basis for creating therapeutic monoclonal antibodies.

Dr. Riggs earned his B.A. in chemistry from the University of California at Riverside and his Ph.D. in biochemistry from the California Institute of Technology, and conducted hisis postdoctoral training at the Salk Institute.

John C. Williams, Ph.D.
Co-founder, Meditope Biosciences

Dr. Williams is an associate professor of molecular medicine at the Beckman Research Institute of the City of Hope, where he also serves as a member of the Developmental Cancer Therapeutics Program as well as Co-Director of the Drug Discovery and Structural Biology Core.

The main focus of Dr. Williams' research centers on the application of structural and biophysical methods to understand the biological role of multivalency and energy additivity on multicomponent, macromolecular complexes and how to manipulate these properties to develop novel, highly specific antagonists. Recently, his lab discovered the meditope binding site while investigating alternative masking agents for cetuximab.

Dr. Williams earned his B.S. in chemistry from the University of California at Santa Cruz and his Ph.D. in chemistry from Columbia University. He was an Alexander von Humboldt postdoctoral fellow at the European Molecular Biology Laboratories in Heidelberg, Germany and an HHMI and Leukemia and Lymphoma Society Special Fellow at Columbia-Presbyterian Medical Center.

Carving a New Space

Learn about how our SnAP technology creates a unique binding site within the Fab region that adds functionality to monoclonal antibodies.


» Learn More